Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’
dc.contributor.author | Watts, G. | |
dc.contributor.author | Norman, Richard | |
dc.date.accessioned | 2018-06-29T12:27:32Z | |
dc.date.available | 2018-06-29T12:27:32Z | |
dc.date.created | 2018-06-29T12:08:40Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Watts, G. and Norman, R. 2018. Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’ [Editorial]. International Journal of Cardiology. 267: pp: 193-194. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/68873 | |
dc.identifier.doi | 10.1016/j.ijcard.2018.06.003 | |
dc.description.abstract |
Seminal data from population genetics have presaged the development of several novel lipid-regulating drugs and the prospect of more effectively addressing high residual risk of cardiovascular disease (CVD) in patients receiving secondary prevention therapies [1]. The most impressive development is the identification of proprotein convertase subtilisin/kexin type 9 (PCSK9), a regulator of the intracellular cycling of the low-density lipoprotein (LDL) receptor, as a target for lowering LDL-cholesterol (LDL-C) [2]. This journey most recently entered the phase of large scale CV outcome trials [2]. The most widely tested method for inhibiting PCSK9 entails the use of humanized monoclonal antibodies (mAbs) [2]. However, their high acquisition costs and budgeting impact on healthcare are concerning [3]. In this issue, Kumar et al. report an economic evaluation of PCSK9 inhibitors in Australia [4]. The secondary prevention population relates to the FOURIER trial [5]. Relative to placebo, they estimated an incremental cost-effectiveness ratio (ICER), reporting the cost per quality-adjusted life year (QALY) being higher than $300,000 [4]. The authors concluded that a significant reduction in cost is required to reach the point at which PCSK9 inhibitors can be recommended as cost-effective, an appropriate conclusion. There are a number of considerations, both clinical and economic, pointing to future research for demonstrating cost-effectiveness in specific populations. | |
dc.publisher | Elsevier Ireland Ltd. | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’ | |
dc.type | Journal Article | |
dcterms.source.issn | 0167-5273 | |
dcterms.source.title | International Journal of Cardiology | |
curtin.department | School of Public Health | |
curtin.accessStatus | Open access | |
curtin.contributor.orcid | Norman, Richard [0000-0002-3112-3893] |